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Abstract
Insulin is a polypeptide hormone produced by the β cells present in Islets of Langerhans of the pancreas. Either
failure to produce (type 1 diabetes) or utilize insulin (type 2 diabetes) causes diabetes mellitus. Insulin administration
is used to treat type 1 diabetes. The common route for insulin administration is via subcutaneous injection. The oral
insulin delivery has been proposed, however it suffers from poor bioavailability which is mainly due to the presence of
proteolytic enzymes (pepsin, trypsin, and chymotrypsin) in the gastrointestinal (GI) tract. Protecting insulin from these
enzymes when given orally might improve its bioavailability. In general, condensed tannins have been shown to reduce
the activity of digestive enzymes. Epigallocatechin-3-gallate (EGCG) is the most abundant tannin component found
in green tea. The present study investigated the ability of EGCG to protect insulin, through the formation of EGCGinsulin complex, from the proteolytic enzyme action by pepsin and trypsin/chymotrypsin, in vitro. The amount of insulin
remaining in the presence and absence of EGCG following incubation with either simulated gastric fluid (SGF) containing
pepsin or simulated intestinal fluid (SIF) containing trypsin/chymotrypsin at two different temperatures (25°C and 37°C)
for 1 hour and 7 hours was determined using an HPLC technique. The results showed that the presence of proteolytic
enzymes (pepsin or trypsin/chymotrypsin) and absence of EGCG in the sample negatively affected the stability of insulin
in solution. In the presence of EGCG, insulin was partially protected from trypsin/chymotrypsin but it was not protected
from the action of pepsin. Insulin degradation was more pronounced at 37°C than that at 25°C (p = 0.0188). The initial
concentration of insulin present (10 IU/mL or 20 IU/mL) or the time of incubation (1 h vs. 7 h) had no influence on the
stability of insulin in the sample (p = 0.2842 and p = 0.2114, respectively). In conclusion, EGCG was not able to protect
insulin against the proteolytic activity of pepsin. However, EGCG was shown to have some protective effect on insulin
against the degradative effect of trypsin/chymotrypsin at room temperature, in vitro. Furthermore, this protection was
greatly weakened at 37°C, which suggested that the protective action of EGCG would not be present in vivo.

Keywords: Epigallocatechin-3-gallate; Green tea; Human insulin;
Oral delivery of peptides and proteins proteolytic enzymes
Introduction
Diabetes mellitus is a disease characterized by disturbances in the
regular metabolism of carbohydrates, proteins and fats. Glucose enters
cells with the assistance of insulin, however in the case of diabetes
mellitus the movement of glucose into the adipose and skeletal muscle
cells is reduced and thereby results in the decreased levels of glycogen
[1]. Insulin is a protein (polypeptide hormone) produced by the β
cells of the pancreas and is chemically composed of two polypeptide
chains connected through two intermolecular disulfide bridges. The
two polypeptide chains are named chain A and chain B with 21 and 30
amino acids respectively [2]. The free glucose circulating in the blood
enters into the liver, muscles, and adipose tissues through insulin by
stimulating the enzymatic reactions at the insulin receptors on the cell
membrane. Membrane phosphorylation occurs by the stimulation
of an intrinsic tyrosine kinase of the insulin receptor. It results in
an enhancement of cell membrane permeability to glucose which
involves some series of intracellular events [3]. Insulin is commonly
administered in the form of subcutaneous injection, but there are
several drawbacks associated with it, such as patient incompliance,
local discomfort, and occasional hyper-insulinemia because of
overdose [4,5]. Alternative routes of insulin delivery have been
proposed such as per-oral (enteric-gastrointestinal) route, oral-buccal
and sublingual routes, rectal delivery, ocular and intravaginal routes,
transdermal delivery, intranasal delivery, and pulmonary route [6,7].
Although the majority of these non-invasive routes have not produced
acceptable safety or efficacy profiles [7], such as the case with polymerencapsulated-insulin delivery [8], the nasal and oral routes remain the
most promising for the insulin delivery [4].
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Overall, the oral route is considered to be a patient-friendly mode
of administration. However, protein administration suffers from
poor bioavailability when given orally. Pharmaceutical scientists have
adopted several strategies in order to improve on the bioavailability
of orally administered insulin. Among these novel approaches
were protecting insulin from the enzymatic degradation using antiproteolytic agents; penetration enhancers to increase gastrointestinal
absorption of insulin; improving the stability of insulin by making
some chemical modification to it; enhancing the contact of drugs
with the mucus lining of the GI tract using the bio adhesive delivery
systems; and using various carrier systems like nanoparticles and
microspheres to improve the insulin bioavailability [4]. Oral insulin
is easy to administer, has better patient compliance, has low index of
intrusion which results in glycemic control, and also lowers the diabetic
complications [9]. High porto-systemic gradient can be obtained by
oral insulin because it is delivered from the GI tract to the liver. It
mimics in that way the natural pathway for insulin handling by the
body [10].
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Tannins are the polyphenolic secondary metabolites obtained
from the higher group of plants which can be either galloyl esters
or their derivatives [11]. These are the complex organic and nonnitrogenous plant products with astringent properties [12]. The
studies conducted on experimental animals and on cell cultures using
tannins have revealed that these compounds have various useful effects.
According to these studies, it is believed that there are two different
ways by which the tannins interact with proteins either by forming
a non-absorbable complex structure or an absorbable complex with
the proteins [13]. One of the important tannins known to man is
Epigallocatechin-3-gallate (EGCG). It is a tannin component found
in green tea (Camellia sinensis). In experimental animals, EGCG acted
in a similar manner to insulin in reducing blood glucose in mammals
through phosphorylation induction of insulin-sensitive residues on
the transcription factor FOXO1a [14]. Previous studies have shown
that the condensed tannins have decreased the activity of digestive
enzymes obtained from various parts of rats and chicken intestinal
tracts. Moreover, the activities of trypsin and α-amylase were reduced
in various parts of the small intestine of rats after feeding them with
the tannin-rich extracts obtained from different fodder plants [15]
which may be associated with the ability of EGCG to bind with crossbeta sheet aggregation intermediates of proteins [16]. Moreover, this
inhibitory effect of EGCG on proteolytic enzymes (e.g., trypsin) was
shown to be due to binding of EGCG to the enzymes through hydrogen
bound formation [17], and this binding capability may be reversed by
salivary proline-rich proteins [18]. Although EGCG had an inhibitory
action on trypsin and chymotrypsin, it had no effect on the action of
pepsin [18,19].

Chemical

Manufacturer

(−)- Epigallocatechin gallate (MW = 458.37
Daltons)

Sigma-Aldrich

Humulin-R (100 IU/mL)- Regular insulin human
injection, USP (rDNA origin) [1 IU/mL = 0.0347
mg/mL]

Eli-Lilly

Acetonitrile

Fischer Scientific

Trifluoroacetic acid

Fischer Scientific

Isopropyl alcohol

EMD

Potassium phosphate monobasic

Sigma Life Sciences

Sodium chloride

Sigma-Aldrich

Porcine trypsin (1:250), Gamma Irradiated

Sigma-Aldrich

Pepsin from porcine gastric mucosa (≥ 250 units/
mg solid)

Sigma Life Sciences

α- chymotrypsin (EC 3.4.21.1, Type II: From
bovine pancreas)

Sigma Life Sciences

Sodium hydroxide

Sigma-Aldrich

pH 7.00 buffer Contents: Orion 910107

ThermoElectron Corporation

pH 4.01 buffer Contents: Orion 910104

ThermoElectron Corporation

Hydrochloric acid (HCl) 12 N

Sigma-Aldrich

Table 1: List of materials used.
Equipment and Model

Manufacturer

Microbalance

Sigma Life Sciences

EGCG was shown to be capable of binding to insulin by
hydrophobic interactions and by the formation of hydrogen bounds
[20,21]. The present study investigated the ability of EGCG to protect
insulin, through the formation of EGCG-insulin complex, from the
proteolytic enzyme action by pepsin and trypsin/chymotrypsin, in
vitro.

UV-Vis spectrophotometer

Agilent

Methodology

Transfer pipets (Disposable Polyethylene)

Fischer Scientific

Vortex machine (Model: Genie 2)

Fischer Scientific

Materials

Spectrophotometer cell (Cuvette) Capacity: 0.7 mL,
VWR International
10 mm light path
Micropipette Capacity: 5000 μL

Gilson

Volumetric flasks Capacity: 5 mL, 10 mL, 25 mL,
Pyrex
and 100 mL

HPLC clear shell vials w/plugs, Capacity: 1 mL

VWR International

Table 1 and Table 2 shows the list of materials and equipment used,
respectively.

Centrifuge

Sorvall Instruments

Methods

Weighing balance Model: AE163

Centrifuge rotor Fixed angle: SS-34 05 20,000 rpm Sorvall Instruments
Mettler

Ultraviolet (UV) spectrophotometry: Using a saturated solution
of EGCG [the maximum solubility of EGCG in water is 25 mg per 1
mL (0.055 M) at room temperature [6]], the detection wavelengths of
EGCG were found to be at 206 nm and 274 nm.

Micropipettes, Capacity: 10 μL, 20 μL, 100 μL, 1000
Gilson
μL, 5000 μL
Micropipette tips Capacity: 100 μL, 1000 μL

Biohit

HPLC (LC-10AD)

Shimadzu

High Performance Liquid Chromatography Method (HPLC)
for human insulin: The parameters used on the HPLC system for
the quantification of the human insulin are shown in Table 3. A high
linear correlation was observed for the calibration curve (1 IU/mL to
100 IU/mL; R2 = 0.9993; p < 0.0001). No interference with insulin peak
was detected in the presence of proteolytic enzymes or EGCG. A peak
for EGCG was also detected with the same HPLC conditions, except
for using 274 nm as a detection wavelength. No interference with the
insulin peak was observed when EGCG and/or proteolytic enzymes
were present in solution (Table 3).

UV-Vis detector (Model:SPD-10A)

Shimadzu

Degasser (DGV-14A)

Shimadzu

Determination of binding efficiency of EGCG and insulin:
Insulin solutions (1 IU/mL to 40 IU/mL; 0.006 mmol/L to 0.24 mmol/L)
were prepared in duplicate and mixed with an equal volume of EGCG
solution (25 mg/mL; 0.055 M). The mixtures were kept undisturbed for

pH meter (benchtop) Model: Orion 3 star

Clin Pharmacol Biopharm
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Peak Simple Chromatography Data System (6
SRI Instruments
channel USP port)
Autosampler

Waters

C4 protein column Dimensions: 15 cm × 4.6 mm

Vydac

Syringes (TB syringes, slip tip with Intradermal
EXEL International
Bevel Needle) Capacity: 1 mL
Millex 0.22 μm Syringe-driven Filter Unit (PVDF
Millipore
filters)
Thermo Electron Corporation

Syringes, Capacity: 10 mL disposable, Model: 10
EXEL International
mL Luer slip tip
Table-2: List of equipment used.
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Parameter

Value

Injection Volume

15 μL

Flow Rate

2.0 mL/min

Wavelength

215 nm

Run Time

20 minutes

Column

Vydac C4 protein column
(15 cm × 4.6 mm)

Mobile phase
Component A

Acetonitrile (10-60%) with 0.05%
Trifluoroacetic acid

Component B

Water (90-40%) with 0.05% Trifluoroacetic
acid

Method used

Gradient elution

Table-3: HPLC parameters for the quantification of insulin.

one hour at room temperature, to allow sufficient complex formation.
After one hour incubation, the mixtures were centrifuged at a speed
of 12,000 rpm for 20 minutes at 25°C. Following centrifugation, the
supernatant was collected from each tube and was analyzed for insulin
using HPLC.
pH adjustment studies: The purpose of these experiments was to
determine the volume of either 50% w/v NaOH or 12 N HCl needed
to affect a change in pH of solution containing proteolytic enzymes
for deactivating pepsin or trypsin/chymotrypsin, respectively. For
proper proteolytic action, pepsin requires an acidic pH and trypsin/
chymotrypsin combination requires a neutral to basic pH. Thus, by
changing the pH of the solution containing pepsin to a basic pH or that
containing trypsin/chymotrypsin to an acidic pH would immediately
halt the enzymatic action on insulin by the enzymes [23]. Simulated
Gastric Fluid (SGF) was prepared by dissolving 0.0225 g of sodium
chloride and 0.0332 g of pepsin in 7-mL of distilled water. To the
mixture, 0.07 mL of 12 N HCl was added using a micropipette and the
final volume was made to 10 mL using distilled water. The pH of the
final solution was adjusted to 1.2 using 15 μL of 12N HCl. Simulated
Intestinal Fluid (SIF) was prepared by dissolving 0.0679 g of monobasic
potassium phosphate, 0.0509g of trypsin, and 0.0502 g of chymotrypsin
in 1.9 mL of 0.2 N sodium hydroxide solution and the final volume was
made to 10 mL using distilled water. The pH of the above solution was
adjusted to 7.6 using 50% w/v NaOH solution. Solutions containing
EGCG-insulin (10 IU/mL or 20 IU/mL; 0.06 mmol/L or 0.12 mmol/L)
in the presence of SGF or SIF (Test Group) were treated with 50% w/v
NaOH or 12 N HCl, respectively in order to halt the degradative action
of the enzymes on insulin. In addition solutions containing only insulin
(10 IU/mL or 20 IU/mL) with SGF or SIF (Control I) or only EGCG
(0.055 M) with SGF or SIF (Control II) were also adjusted to basic pH
or acidic pH with 50% NaOH or 12 N HCl, respectively. Samples were
treated for either 1 h or 7 h under aforementioned conditions prior to
adding the 50% NaOH or 12 N HCl. The volume of 50% w/v NaOH
and 12 N HCl needed to affect this change in pH were recorded (Table
4, Table 5). For all the samples prepared, the concentration units listed
for the various components reflected those found prior to mixing with
SGF or SIF solutions. SGF and SIF solutions were mixed with solutions
containing only insulin, only EGCG, or only EGCG-insulin complex
in a ratio of 1:2 (v/v) (sample:SGF or sample:SIF) (actual volumes were
100 µL of sample mixed with 200 µL of proteolytic enzyme solution).
Effect of proteolytic enzymes on the stability of insulin in the
presence and absence of aqueous EGCG solution: An experiment
Clin Pharmacol Biopharm
ISSN: 2167-065X CPB, an open access journal

was conducted to determine the effect of proteolytic enzymes on the
stability of insulin in the presence (0.055 M) and absence of EGCG
solution. Solutions containing EGCG-insulin (10 IU/mL or 20 IU/
mL; 0.06 mmol/L or 0.12 mmol/L) in the presence of SGF or SIF (Test
Group) and solutions containing only insulin (10 IU/mL or 20 IU/
mL) with SGF or SIF (Control I) or only EGCG (0.055 M) with SGF
or SIF (Control II) were prepared (Control II samples were used to
ascertain that the conditions of incubation used did not interfere with
the insulin peak on HPLC assay. As stated above, no interference with
the insulin peak was observed when EGCG and/or proteolytic enzymes
were present in solution). Samples were treated for either 1 h or 7 h in
triplicates and kept under 25°C or 37°C (insulin was stable under those
conditions if proteolytic enzymes were not added to solution). After
pH adjustment to halt the action of proteolytic enzymes on insulin
degradation as specified above, the samples were filtered and analyzed
on HPLC for their content of insulin. For all the samples prepared, the
concentration units listed for the various components reflected those
found prior to mixing with SGF or SIF solutions. SGF and SIF solutions
were mixed with solutions containing only insulin, only EGCG, or only
EGCG-insulin complex in a ratio of 1:2 (v/v) (sample: SGF or sample:
SIF) (actual volumes were 100 µL of sample mixed with 200 µL of
proteolytic enzyme solution).
Statistical analysis: JMP Statistical Discovery Software (SAS
Institute, Cary, NC) was used for the statistical analysis. A multifactorial
analysis of variance method (MANOVA) was used to test the difference
in insulin content (the dependent variable) remaining following the
treatment with the enzymes in the presence of EGCG. The independent
variables were the initial concentration of insulin present (10 IU/mL
and 20 IU/mL), temperature (25°C and 37°C), and time of exposure
to enzymes (1 h and 7 h). A p value of less than 5% was considered
significant.

Results
The percentage of insulin bound to ECGC following incubation at
25°C for 1 hour is shown in Figure 1.
The volume (µL) of 50% NaOH or 12 N HCl needed to affect a
change in pH are shown in Table 4 and Table 5, respectively. The
effect of proteolytic enzymes on insulin (10 IU/mL or 20 IU/mL; 0.06
mmol/L or 0.12 mmol/L) degradation in the presence or absence of
ECGC (25 mg/mL; 0.055 M) at different temperatures (25°C and 37°C)
for 1 h or 7 h incubation periods is shown in Figure 2.

Discussion
For the initial concentrations of insulin used in this study (1 IU/
mL to 40 IU/mL; 0.006 mmol/L to 0.24 mmol/L), almost all the insulin
present in solution formed a complex with EGCG (mean ± S.D. 95.9%
± 5.6%; n = 12; 95% CI = 92.3% - 99.5%) (Figure 1) Wang et al. [24] have
shown that EGCG directly bound to insulin primarily via hydrogen
bond formation, and that the binding was independent of pH and
temperature. In addition to hydrogen bound formation, EGCG-insulin
complex was also held together by hydrophobic interactions [20,21].
The hydrogen bounds were expected to form between the hydroxyl
groups of EGCG and certain currently undefined amino acid residues
on insulin chain [18]. Insulin was quickly and completely degraded
by SGF (pepsin) with or without EGCG being present in the solution
(Figure 2). This agrees with the results obtained from a previous study
where the proteolytic action of pepsin (SGF) on free insulin was
completed within one minute of incubation with the enzyme [2]. Also,
EGCG was shown to be unable to halt the enzymatic activity of pepsin,
and in some cases even enhanced the proteolytic action of pepsin
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[19]. Naz et al. [18] have shown that EGCG inhibited several digestive
enzymes in the following descending order -amylase > chymotrypsin
> trypsin > lactase; negligible or no inhibition of pepsin by EGCG was
noted in these experiments.
The destruction of free insulin by trypsin/chymotrypsin (SIF) in
the absence of an enzyme inhibitor was found to follow a first-order
type reaction with a first-order degradation rate constant of 0.069
min-1 at 37°C, in vitro [23]. A multifactorial analysis of variance test
(MANOVA) was performed on the data obtained from the insulin
degradation experiments with SIF (trypsin/chymotrypsin) and in the
presence of EGCG-insulin complex. [In the absence of EGCG, all of
the insulin was degraded by trypsin/chymotrypsin (Figure 2)]. Based
on the analysis of the results (Figure 2), the temperature was the only
factor that significantly (p = 0.0188) affected the amount of insulin
remaining in solution following treatment with trypsin/chymotrypsin
(Figure 3).
The effect of the proteolytic enzymes on insulin was halted at the
end of the experiment [23] by changing the pH of the sample from
(average ± S.D.; n = 20) 2.58 ± 0.62 to 8.06 ± 0.57 in the case of pepsin,
and from 7.64 ± 0.48 to 1.47 0.73 for trypsin/chymotrypsin samples
(Tables 4 and 5). Under those pH conditions, free insulin existed as a
monomer (pH ∼ 2.0) or as a dimer (pH ∼ 7.4) in solution. Moreover,
the presence of EGCG in solutions containing insulin was shown to
prevent insulin aggregation to some extent; this aggregation prevention
reached its maximum point at insulin concentration in the range of
0.1-0.2 mmol/L [24] (in the present study, the insulin concentration
was 0.06 mmol/L or 0.12 mmol/L). Samples containing EGCG-insulin

Figure-1: Percentage of insulin bound to EGCG (25 mg/mL) at room
temperature following one hour incubation. Insulin solutions (1 IU/mL to 40
IU/mL; 0.006 mmol/L to 0.24 mmol/L) were prepared in duplicate and mixed
with an equal volume of EGCG solution (25 mg/mL; 0.055 M). Each error bar
is constructed using one standard deviation from the mean.

S.No

Conc. of Insulin added
(IU/mL)

Proteolytic
enzymes added

Incubation period
(h)

Temperature (°C)

Initial pH

Volume of 50% w/v
NaOH added (μL)

Final pH

1
2

10

SGF

1

25

1.77

3

8.12

10

SGF

7

25

2.20

2

8.64

3

10

4

10

SGF

1

37

1.67

2

7.86

SGF

7

37

2.60

2

7.62

5

0

6

0

SGF

1

25

2.60

2

7.91

SGF

7

25

2.63

2

8.62

7

0

SGF

1

37

2.52

2

9.82

Sample

Control I
(10 IU/mL)

Control II
(EGCG 0.055 M)

8

0

SGF

7

37

3.24

2

8.12

9

10

SGF

1

25

2.56

2

7.47

SGF

7

25

2.33

2

7.71

SGF

1

37

2.91

2

7.96

Test group
(EGCG-insulin
complex)

10

10

11

10

12

10

SGF

7

37

2.39

2

7.42

13

20

SGF

1

25

2.45

2

7.57

14

20

SGF

7

25

2.41

2

8.04

15

20

SGF

1

37

2.03

2

8.24

16

20

SGF

7

37

4.72

2

7.62

17

20

SGF

1

25

2.69

2

7.44

18

20

SGF

7

25

2.82

2

8.64

19

20

SGF

1

37

2.60

3

8.06

20

20

SGF

7

37

2.39

4

8.34

Average ± SD

2.58 ± 0.62

2.2 ± 0.5 µL

8.06 ± 0.57

Control I
(20 IU/mL)

Test group
(EGCG-insulin
complex)

Table-4: Volumes of 50% w/v NaOH used for pH adjustment of the samples.
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S.No

Conc. of Insulin
added (IU/mL)

Proteolytic
enzymes

Incubation period
(h)

Temperature (°C)

Initial pH

Volume of 12 N HCl
added (μL)

Final pH

1

10

2

10

SIF

1

25

6.81

2

1.54

SIF

7

25

7.48

6

3

10

1.40

SIF

1

37

7.06

2

4

1.54

10

SIF

7

37

7.85

9

1.28

5

0

SIF

1

25

8.08

6

1.22

6

0

SIF

7

25

8.12

6

1.24

7

0

SIF

1

37

8.61

6

1.25

8

0

SIF

7

37

7.74

7

1.22

9

10

SIF

1

25

7.92

8

1.45

10

10

SIF

7

25

6.68

7

1.24

11

10

SIF

1

37

8.22

6

1.28

12

10

SIF

7

37

7.62

6

1.24

13

20

SIF

1

25

8.12

6

1.32

14

20

SIF

7

25

7.58

5

1.28

15

20

SIF

1

37

7.52

5

1.30

16

20

SIF

7

37

7.52

4

1.33

17

20

SIF

1

25

7.70

8

1.31

18

20

SIF

7

25

7.07

5

1.25

19

20

SIF

1

37

7.56

5

1.36

20

20

SIF

7

37

7.49

3

1.25

Average ± SD

7.64 ± 0.48

5.6 ± 1.8 µL

1.47 ± 0.73

Sample

Control I
(10 IU/mL)

Control II
(EGCG 0.055 M)

Test group
(EGCG-insulin
complex)

Control I
(20 IU/mL)

Test group
(EGCG-insulin
complex)

Table-5: Volumes of 12 N HCl used for pH adjustment of the samples.

Figure-2: Percentage of insulin remaining after treatment with proteolytic enzymes (SGF = pepsin; SIF = trypsin/chymotrypsin) incubated at either 25°C or 37°C
for 1 h or 7 h in the presence or absence of EGCG (25 mg/mL; 0.055 M). Initial concentration of insulin was 10 IU/mL or 20 IU/mL (0.06 mmol/L or 0.12 mmol/L).
Each error bar was constructed using 1 standard error from the mean (n=6).
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Figure-3: Profiler for the input factors and their values to produce a maximized value (by maximizing the desirability function) in the outcome: Proteolytic enzyme =
SIF (trypsin/chymotrypsin), incubation time = 1 or 7 hours (p = 0.2114), temperature = 25°C or 37°C (p = 0.0188), and initial concentration of insulin = 10 or 20 IU/mL
(p = 0.2842). Given incubation time of 7 hours, a temperature of 25°C, and an initial concentration of insulin of 20 IU/mL, the predicted percentage of insulin remaining
was 103.86% (95% CI = 64.68% to 143.05%).

Figure-4: Profiler for the input factors and their collective effects on the outcome: Proteolytic enzyme = SIF (trypsin/chymotrypsin), incubation time = 7 hours,
temperature = 37°C, and initial concentration of insulin = 20 IU/mL. Given these conditions, the predicted percentage of insulin remaining was 30.56% [95% CI =
-8.62% to 69.75%].

complex and treated with trypsin/chymotrypsin had more pronounced
Insulin degradation at 37°C than that at 25°C (p = 0.0188). On the
other hand, the initial concentration of insulin present (10 IU/mL or
20 IU/mL) or the time of incubation (1 h vs. 7 h) had no influence
on the stability of insulin in the sample (p = 0.2842 and p = 0.3012,
respectively) (Figure-3). EGCG demonstrated no protective action
on insulin in the presence of pepsin (SGF) under the experimental
conditions, while it protected insulin to a certain degree when the
hormone was incubated with SIF (trypsin/chymotrypsin) (Figure-2).
This perhaps was due to the difference between pepsin and trypsin/
chymotrypsin action on insulin. Human insulin is composed of 51
amino acids forming two chains (A and B). Disulfide bonds link the
two chains together at specific locations [25]. Trypsin cleaves insulin
at the following locations B29-Lys and B22-Arg, while chymotrypsin
attacks insulin at locations A11-Cys, A14-Tyr, A19-Tyr, B1-Phe, B15Leu, B16-Tyr, B25-Phe, and B26-Tyr [26] Insulin chains are much
more susceptible to the attack by pepsin as the enzyme is capable to
cleave the chain at 15 locations (four sites in the region of A13-A19,
five spots in A2-A8 segment, and six positions located in the B chain)
[26]. Since pepsin action was fast and complete in degrading insulin
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held within the EGCG-insulin complex, this could point out to the
fact that the hydrogen bound formation and hydrophobic interactions
between insulin and EGCG were not sufficient enough to shield the
aforementioned vulnerable sites available on insulin chain from the
proteolytic action of pepsin, keeping some or all of these sites exposed
to the damaging effect of the enzyme. On the other hand, the protective
effect of EGCG on insulin seen with SIF was perhaps related in part to
the EGCG-insulin complex’s three-dimensional structure formation in
protecting to some degree the 10 susceptible sites from the degradative
action of trypsin (two locations) and chymotrypsin (eight locations).
Analysis of data indicated that EGCG-insulin complex could resist
the proteolytic degradation imposed by trypsin/chymotrypsin for a
period of 7 hours with a concentration of insulin in solution of 20 IU/
mL and stored at room temperature (Figure 3). However, a change in
temperature from 25°C to 37°C would cause almost a total destruction of
insulin, present in the solution in the form of EGCG-insulin complex,
by trypsin/chymotrypsin (predicted insulin remaining = 30.56%; 95%
CI = -8.62% to 69.75%) (Figure 4).
Thus,

EGCG-insulin

complex’s

degradation

by

trypsin/
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chymotrypsin appears to be highly sensitive to a rise in temperature.
One explanation to that might be that the vulnerable sites on insulin
chain that were normally susceptible to trypsin/chymotrypsin action
and were originally shielded by EGCG-insulin complex formation
became exposed to the enzymes at higher temperatures (37°C). Perhaps
this was related to hydrogen bounds weakening as the temperature
increased from 25°C to 37°C [27]. Further investigations are needed
to ascertain this temperature-dependent sensitivity of the complex
to its denaturation by the enzymes. The implication of this study
is that although insulin could form a complex with EGCG at room
temperature, shielding its susceptible sites from trypsin/chymotrypsin
proteolytic action, this protection lessened greatly and perhaps totally
disappeared, at 37°C. Thus, the oral administration of EGCG-insulin
complex in a form of enteric coated delivery system (to protect
insulin from the action of pepsin) would not be expected to render
any improvement in insulin bioavailability over that seen with insulin
alone. Furthermore, any freed EGCG from the complex would not be
expected to have a significant inhibitory activity on the enzymes (i.e.,
trypsin and chymotrypsin) in vivo because of the presence of salivary
proline-rich proteins would protect the digestive enzymes from EGCG
inhibitory effect [18]. From all practical points of view, EGCG cannot
be expected to protect insulin administered orally from the degradative
proteolytic action presents in the GI track.

Conclusions
In summary, the complex formation between EGCG and insulin
did not protect insulin from the proteolytic action of pepsin, while
EGCG-insulin complex rendered the degradative activity of trypsin
and chymotrypsin on insulin less pronounced at room temperature.
The stability of insulin in solution as EGCG-insulin complex in the
presence of trypsin/chymotrypsin was found to be temperaturedependent. EGCG did not protect insulin from the action of proteolytic
enzymes at 37°C, the one expected to be encountered in vivo.
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